GlassScriptPhysician profile
Jose Antony Paul
NPI 1629219936
$5,957.60
in general payments reported to CMS, 2019-2025
24 companies · $816 in 2025
The $816 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $137 · 2020: $47.64 · 2022: $1,923 · 2023: $2,210 · 2024: $825 · 2025: $816.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $2,006 · Food and Beverage: $1,844.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $2,006.05 |
| Food and Beverage | $1,844.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Steris Corporation | $2,064.77 | 2023 | |
| Intuitive Surgical, INC. | $999.11 | 2022-2024 | |
| Pinnacle Biologics, INC | $931.85 | 2022 | |
| Pulmonx Corporation | $381.34 | 2019-2024 | Chartis Catheter, Zephyr Endobronchial Valve, Pulmonx Chartis Tablet Console |
| Glaxosmithkline, LLC. | $302.94 | 2024-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Astrazeneca Pharmaceuticals LP | $275.90 | 2024-2025 | Fasenra, Tezspire, Breztri |
| Grifols USA, LLC | $227.26 | 2024-2025 | Prolastin-C Liquid, Xembify |
| Olympus America INC. | $146.78 | 2025 | Spiration Valve System |
| Boehringer Ingelheim Pharmaceuticals, INC. | $122.31 | 2019-2025 | Ofev |
| Baxter Healthcare | $77.42 | 2024-2025 | Hillrom - Vest System Model 105 Home Care |
| Genzyme Corporation | $74.49 | 2024-2025 | |
| Insmed, INC. | $47.74 | 2020-2023 | Arikayce |
| Jazz Pharmaceuticals INC. | $42.22 | 2024 | |
| Actelion Pharmaceuticals US, INC. | $38.90 | 2024 | Opsumit, Uptravi |
| Pfizer INC. | $37.48 | 2024-2025 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $31.27 | 2025 | Dupixent |
| Resmed Corp | $29.59 | 2024 | |
| Ani Pharmaceuticals, INC. | $23.15 | 2024 | Purified Cortrophin Gel |
| Mallinckrodt Hospital Products INC. | $22.72 | 2025 | Terlivaz |
| Mylan Specialty L.P. | $18.11 | 2024 | Yupelri |
| Merck Sharp & Dohme LLC | $17.39 | 2025 | Winrevair |
| Takeda Pharmaceuticals U.S.A., INC. | $16.16 | 2025 | Glassia |
| Galvanize Therapeutics, INC | $15.15 | 2024 | Aliya System |
| Verona Pharma, INC. | $13.55 | 2025 | Ohtuvayre |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jose Antony Paul listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.